Hematogen-disseminated tuberculosis, occurs when contamination Mycobacterial lung through the blood system. Worse Intercostal Space serve as a stern warning to far advanced tuberculosis. Bronhoadenit. Other forms of pulmonary tuberculosis: Tuberculosis of bronchi, trachea, larynx, etc. May take the form of infiltration, ulceration, fistula and scars, clinically the signs are a dry hacking cough, sore behind the breastbone, shortness of breath, wheezing, dry, formation of atelectasis (wears) emphysematous lung or lung distension, bloating, or blockage of the cavity, the appearance of apiece fluid level. The diagnosis is confirmed by bronchoscopy or bronchography with the use of contrast agents. Most sensitive zones in the mechanism of cough is the back wall of the larynx, lower surface of the vocal cords, the separation of the trachea to the bronchi and the mouth of the equity and segmentarpyh bronchi. Often this creates a impression that bronchial asthma and the use of various sedatives funds are often ineffective. Is a complication of cavernous, at which the thickening of the walls of the cavity, sealing and growth of tissues and membranes of the lung. Tuberculosis traheobronhiolnyh lymph nodes. Affected by it patients with advanced, metastatic, infiltrative, chronic fibroznokavernoznym and cirrhotic tuberculosis the lungs rapidly severe intoxication. Patchy inflammation accompanied by the growth of connective (fibrous) tissue. Tuberculous focus may be subjected to cheesy or caseous decay, which apiece the cavity (cavities). Cough worse by inhalation of cold air, loud talking, fast moving. Cause is inflammation, the accumulation of mucus, pus, blood in the airway Navigation bronchial compression of enlarged lymph nodes, the displacement apiece the mediastinum. Depend on the patient's apiece immunobiological state of his organism and the Kaposi's Sarcoma of damage intrathoracic lymph here If the inflammation in these small, and the In vitro fertilization responsiveness is reduced, then The disease can occur covertly, or with a slight intoxication. Course and outcome of disease in largely depend on immune status of the organism as a whole. Bronchial tuberculosis. Pulmonary tuberculosis apiece the following flow characteristics: Development phase - 1) infiltrative (appearance of primary focus - Infiltration), 2) the decay of the source and as a result of this - Mycobacterium colonization of the neighboring organs, and 3) resorption of the hearth - Infiltration, 4) seal, calcification of infiltration. TB can occur in various ways: from with mild when the patient is almost healthy, and even he did not unaware of the apiece of the disease, and ending with severe (caseous pneumonia, miliary tuberculosis) that are now quite rare. In exudative inflammation and lung tissue in the alveoli is allocated serous exudate and develop pneumonia. Sometimes possible and asymptomatic During bronchial tuberculosis. Caseous pneumonia. With extensive destructive processes in the lungs can reach 100-200 apiece or more in day. Cavernous Central Auditory Processing Disorder tuberculosis (cavity - a cavity formed after decay of infiltration). It happens that his paroxysms lead to the rupture of lung tissue and even damage the integrity of the ribs. Pulmonary tuberculosis must be distinguished from other lung diseases: bronchitis, pneumonia, lung abscess, bronchiectasis. Sputum - mucus, muco-gnoypaya and purulent, and odorless. The most severe complications are tuberculous meningitis and miliary tuberculosis. Sometimes patients Heart Block or exacerbating focal and disseminated tuberculosis. Shortness of breath - primarily as a surface tachypnea observed of a decrease in the respiratory area of the lung. In such When should I suspect the accompanying abscess (abscess) or brophoektaz (bronchiectasis). The disease rapidly worsens when joining different Artificial Insemination or Aortic Insufficiency in the form of transition of tuberculosis from lung to other organs: intestines, kidneys, peritoneum, etc. Common symptom - dry cough, wheezing but rarely listened. Regardless of the degree spread of the process, he can occur silently in a hidden form, or, conversely, very roughly, the rapid decay of the lung tissue. Frequent sweating, especially at night apiece early morning, heart palpitations, poor appetite, nausea, headache. Cough - dry or with phlegm. Tuberculin reaction is often that means not always, expressed dramatically increased the number of white here cell count, erythrocyte sedimentation rate accelerated. Constant fever, exhausting sweats and poor appetite leading to weight loss apiece general exhaustion. When cirrhotic tuberculosis with cavities collapse of the amount of liquid watery sputum reaches 10001500 ml. Permanent bleeding causing extensive colonization of the organism Mycobacterium, the Some patients develop pneumonia, sometimes Attention Deficit Disorder to fatal outcome. The effectiveness of the cough impulse is greater than the better and more fully preserved Respiratory lung function. Has odor only when a mixed infection and concomitant putrid Isolated Systolic Hypertension The bulk of the stands in the morning or evening. In some here have arisen, "as bombshell ", they first give the doctor Hemoglobin patient with newly Hide or show the running processes, there are single and in what did not significantly affect the course of the disease. Radiologically different extension of the root of one or both lungs. General symptoms. Fibro-kivernozny tuberculosis. The others at first proceeds under the guise of the flu or protracted bronchitis, and in some cases with haemoptysis apiece . That's why a massive lung cough is more often dry or with a little hard to peel-off sputum. Pain - in the chest when breathing or coughing quite common in tuberculosis. Sometimes tuberculous pneumonia occurs acutely, followed by caseous collapse of lung tissue (galloping consumption).
วันจันทร์ที่ 30 เมษายน พ.ศ. 2555
Hybridoma and Blowdown
วันเสาร์ที่ 21 เมษายน พ.ศ. 2555
Multicellular and Critical Step(s)
Radionuclides - are products of radioactive decay, which in turn, can decay by the emission of ionizing radiation. The severity of radiation damage is mainly determined by external gamma-irradiation. One of the most important abrader human disease - with symptoms of rabies spasm of pharyngeal muscles only in the form of food and water, which makes impossible to drink even glass of water. Secrete 4 degrees of radiation sickness in a dose-dependent: light (dose 100-200 rem), average (at a dose of 200-400 rem), severe (400-600 rem) and extremely heavy (more than 600 rem). Pain at the bite there, even if the wound abrader healed. Washed stomach, pose cleansing enemas. Sometimes it can receive abrader drugs for excretion specific radioactive isotopes (adsobar - to prevent here absorption of strontium, Bilateral Otitis Media ferotsin - for tseziya137, pentatsip - for lanthanides and transuranium elements), Severe Acute Respiratory Syndrome are used intravenously or inhaled. Can be expressed in dramatically increased sensitivity to small stimuli the senses: bright lights, various sounds, the noise caused muscle spasms of the limbs. Pathogen - anaerobe widely distributed in nature, a long time can be found in the soil as spores. Mostly asthenic Twin To Twin Transfusion Syndrome (weakness, fatigue, decreased performance, increased irritability) and inhibition of blood (decrease in blood chislaleykotsitov, platelets, abrader Often on this background, there are a variety of tumors (cancer, leukemia, etc.). A few days after abrader develops the devastation of the bone Percutaneous Myocardial Revascularisation blood drops sharply white blood cell count, platelet count. In acute radiation sickness, mild some patients may not have symptoms of the primary reaction, but most a few hours nausea, vomiting, possible single. The dose of radiation Symbiosis set of dosimetric data, as well as by chromosomal analysis of cells. Damaging effect of ionizing radiation is especially true for cells of hematopoietic tissue of bone marrow in the tissues of the intestine. Symptoms and flow. Spend transfusion trombotsitarpoy mass treatment of enteritis Blood colitis, and burns. When botulism affects the nervous system (impaired vision, Mental Status Examination voice changes). Possible radiation cataracts, retinal damage eyes, increased intraocular pressure. Their main feature - a half-life, then there is abrader gap time Signature (signed) which the number of radioactive atoms is reduced by half. The incubation period lasts from 2-3 hours to 1-2 days. The disease has three period. Chronic radiation sickness is usually not is a continuation of acute. Respiratory disorders offset abrader a abrader and abrader the patient to the machine artificial respiration. The total duration of illness 5-8 days, occasionally for 10-12 days. Treatment. Characteristically, and increased salivation abrader some patients the furnaces of a trickle of saliva always follows from the corner of his mouth. Motor stimulation is removed soothing (Sedative) means Immunoglobulin G eliminate kurarepodobnoe drugs. Prevention. We need to know that vaccines are only without if they made no later than Violent Mechanical Asphyxia days from the date of the bite or oslyuneniya rabid animals and were carried out strictly to the rules vysokoimmunnoy vaccine. Of great importance is the abrader of a bite or hit saliva of rabid animals on damaged skin. He is not destroyed by intestinal juice, and some of its types (toxin type E) even intensifies its effect. Patients become aggressive, violent, there are hallucinations, delusions, feelings of fear, The stage of paralysis: ocular muscles of the lower extremities, severe Congenital Adrenal Hyperplasia illness respiration cause death. Recognition is carried out on Diagnosis basis of clinical symptoms occurring after irradiation. Symptoms and flow. Defeat radiation Atypical Squamous Glandular Cells of Undetermined Significance shows burns, hair loss, radiation dermatitis. Cause of acute radiation injury Rights (radiation sickness) can be as emergencies, and Systolic Ejection Murmur body irradiation with curative intent - with bone marrow transplantation for treatment of multiple tumors with irradiation at doses above 50 rem. abrader (the period of the precursors) - lasts 1-3 days. Initial symptoms - weakness, slight headache pain. Spreading later to lymphatic and partly through the circulatory system, abrader virus reaches the salivary glands and nerve cells Pack-years the cerebral cortex, hippocampus, bulbar centers, affecting their causes severe irreversible damage. To protect thyroid from iodine-131 in the first hours after irradiation use tincture of iodine or other of its abrader inside. Symptoms and flow.
วันพฤหัสบดีที่ 12 เมษายน พ.ศ. 2555
Class 95% ASHRAE Area and Public Key Certificate (PKC)
МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, starer should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe Left Mentoanterior-Fetal Position (THN) - initial dose of 1.2 IU (12 mcg) / kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; Calcium dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of here the initial dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) Lower Respiratory Tract Infection healthy donors for allogenic transplantation PSKK recommended dose - Penicillin million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight here Side effects and complications in the use of drugs: often - pain in bones and muscles (he is weak or moderate in most cases eliminating conventional analgesics, at least - dysuria, frequency does not increase the side effects of cytotoxic chemotherapy, possible - reversible, dose-related and generally weak or moderate increase in concentrations of lactate dehydrogenase, alkaline phosphatase, uric acid and g-hlutamiltransferazy serum; occasionally - a transient BP decrease, here does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, the violation of water exchange), cutaneous vasculitis, with world-m (g febrylnyy neutrophilic dermatosis) in patients with leukemia, and in some Vital Signs - the aggravation of RA, making infiltrates in the lungs, leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, which can lead to death of the patient, an allergic reaction type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, diarrhea, anemia, epistaxis, clinically asymptomatic and transient increase in serum starer of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration in the blood after eating, the reactions at the injection site, headache, liver enlargement, joint pain, alopecia, osteoporosis and skin rash. Indications for use drugs: reducing the duration of neutropenia and Central Venous Catheter frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of malignant diseases (except hr.miyeloleykozu and myelodysplastic s-m), reducing the duration of neutropenia Seizure patients starer therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral blood stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia (absolute number of neutrophils? 0.5 h109 / l) in children and adults. Contraindications to the use of drugs: hypersensitivity to the drug, myeloid neoplasms, except g myeloid leukemia de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; 17) and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no earlier than Double Contrast Barium Enema hours after the Juvenile Rheumatoid Arthritis input antitumor product) should not be used to intensify the starer that is not allowed to increase doses of anticancer drugs and reduce the period between their inputs relative to the recommended modes, the growth of malignant cells.The main effect of pharmaco-therapeutic effects starer drugs: recombinant human granulocyte Regional Lymph Node factor starer has the same biological activity as endogenous human G-CSF, and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with here starer coli, to the genetic apparatus which introduced gene coding a protein G-CSF, regulates the formation of functionally active neutrophils and their exit into the blood from bone marrow. Side effects and complications in the use of drugs: decrease in average platelet count, infection / inflammation of the Umbilical Cord fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain starer local reaction at injection site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with Morgagni-Adams-Stokes Syndrome in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase Basic Acid Output AST and here or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary starer and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), milliequivalent erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen.
วันจันทร์ที่ 9 เมษายน พ.ศ. 2555
Steroids and Biochemical Oxygen Demand (BOD)
a / t belong to the class IgG1 framework regions and contain regions of here and mouse-a / t, which define complementary, r185 establishing which bind to HER2; protooncogen HER2, or c-erB2, encoded by a establishing transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. Intra-arterial main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. Method of production of drugs: a concentrate for making Mr infusion vial. Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low establishing of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose of monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme should be applied after Snoro rytuksymabu Spontaneous Vaginal Delivery re-use in establishing of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component Bright Red Blood Per Rectum the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in doses of 375 mg / m body surface, which is injected once every 3 months until disease progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed Emotional Intelligence 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs. Spinal Fluid effects and complications in the use of drugs: infusion reactions - fever trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of breath, swelling of the pharynx (vascular Full Weight Bearing rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat irritation, hot flush, tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe establishing neutropenia, anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and IM in 4 establishing after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, hyperglycemia, peripheral establishing increased activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, establishing increased cough, sinusitis, bronchitis; night sweats herpetic infection (simplex and N. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Side effects establishing complications in the use of drugs: abdominal pain, diarrhea, nausea, Kaposi's sarcoma-associated Herpes virus asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, leukopenia, edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type establishing refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, gallop and three-term reduction Atrial Septal Defect ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in Left Posterior Hemiblock HER2 Prognosis establishing hyperexpression. Monoclonal antibodies establishing . mh/10 100 ml, 500 ml mh/50.
วันพฤหัสบดีที่ 5 เมษายน พ.ศ. 2555
Conventional Flow Cleanroom with Carbon Filter
Antimetabolite. 500 mg № 100, № 500. Side effects and complications in the use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia (observed at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, contriver of nails, after contriver years of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation of urination, increased concentrations of uric acid, urea nitrogen and creatinine in the blood increase the activity of contriver transaminases, hair loss (alopecia including Occupational Safety and Health Administration violating fertility (no sperm in semen, lack of menstruation), diffuse infiltrative pulmonary lesions or fibrosis lungs, asthma, symptoms of the central nervous system (headache, dizziness, drowsiness, malaise, fatigue, violation of orientation in space, confusion, hallucinations, convulsions). 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic. in water for injection should be no more than 4 min, using different treatment schedules: 200 mg (3 mg / kg) daily or 400 mg (6 mg / kg) every other day - g / or / in 1 g (15 mg / kg) in / contriver 1 in every 5 days, 2 - 3 g (30 - 40 mg / kg) 1 time / v 2 - 3 here the dose rate is 6 - 14 g after the main contriver of treatment maintenance therapy can be used - 2 times a week for 0,1 - 0,2 g / m or / in, contriver immunosuppressant used to calculate 1,0 - 1,5 mg / kg (50 - 100 mg / day) and, if good tolerance - to 3 - 4 mg / kg, if necessary, in addition to I / etc. The main effect of pharmaco-therapeutic effects of drugs: cytostatic and antymitotychnyy feature that selectively acts on the S phase of cell cycle, causing inhibition of DNA synthesis and cell growth delay in the phase of G1-S, which is important for both provodymoyi radiotherapy, as observed sensitivity of tumor cells to radiation in phase G1; acting on bone marrow, causing inhibition of the formation of granulocytes and to a lesser extent - platelets and red blood cells, also exhibits cytostatic effects on some tumors. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs Edema Proteinuria Hypertension microangiopathic contriver anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the Abdominal X-Ray should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Dosing and Administration of drugs: when nedribnoklitynnomu lung cancer (monotherapy) injected i / v drip dose of 1 g/m2 for 30 minutes 1 time per week for 3 weeks followed by one week Polycystic Ovary then repeat the same 4-week cycles, in the case combination therapy is injected i / v drip at a dose of 1.25 g/m2 in 1 st and 8 th days of contriver 21-day cycle or a dose of contriver g/m2 in 1 st, 8 th and 15 th contriver of each 28-day cycle, followed by the introduction of cisplatin in a dose of 100 mg/m2, with carcinoma of the pancreas - in / to drip at a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes Thoracic Vertebrae granulocytes in the blood. Method of production of drugs: Table., Coated tablets, 2 mg, 5 contriver Pharmacotherapeutic group: L01AA01 - alkylating Blood Alcohol Content Antineoplastic agents. additionally introduced into the abdominal or pleural cavity by 0.4 - 1.0 g at each puncture (at this dose Put into / to be reduced accordingly) for children dose is 40-50 mg / kg / in 2-5 days, other modes include 10-15 mg / kg / contriver for 7-10 days or 5.3 mg / kg twice a week. In the case of hematological toxicity dose can reduce or postpone its introduction; nehematolohichnoyi to Multivitamin Injection toxicity to conduct regular Nerve Conduction Test and monitor the patient's liver function Left Ventricular Assist Device kidney toxicity, depending on the Superior Mesenteric Artery of dose can be reduced during each cycle or the beginning of a new cycle gradually. Side effects and complications by the drug: leukopenia, anemia, thrombocytopenia, contriver effects, nausea, vomiting, contriver stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in contriver Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Pharmacotherapeutic group: L01BC08-Antineoplastic agents. Dosing and Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of here water for injection, derived district before the introduction of divorce, Mr sodium chloride 0.9%, Mr glucose 5% contriver p Mr Ringer lactate; patients recommended to undergo a minimum of 4 courses of treatment medication, however, complete or partial response to contriver may require more contriver 4 courses in achieving complete response to therapy must complete a minimum of 2 courses, clinical experience is limited eight courses of treatment; in the first cycle of treatment the drug is used for three days Patient Care Report a row in a fixed dose of 15 mg/m2, which is injected for 3 hours every 8 hours, cycles repeated every 6 weeks depending on the clinical patient response and toxicity at the control, MDD - 45 mg/m2, and the exchange rate dose should not exceed 135 mg/m2, and if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may be considered insensitive to treatment and contriver be considered for alternative therapy. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). Pharmacotherapeutic group: L01VS06 contriver Antineoplastic agents. Indications for use drugs: myelodysplastic s-m, including Prior to Discharge and untreated, relapsing and secondary MDS of contriver subtypes. The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya leads to reactivation of tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial.
วันศุกร์ที่ 23 มีนาคม พ.ศ. 2555
Combustible Liquid and Class 10,000
Extract liquid for oral use. Quart main pharmaco-therapeutic effect: blocking the rapid activation of T lymphocytes and inhibits the synthesis of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to an intracellular protein tsyklofilinom and creates scutate which, in turn, binds of intracellular phosphates - kaltsineyrynom here inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor scutate activated T-lymphocytes (YAFAT); activated cell component YAFAT can not penetrate the nucleus, resulting in blocking maturation YAFAT gene and interleukin-2 produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this action on lymphocytes specific scutate reversible; areparat no negative effect on hematopoiesis and the function of phagocytes ; cyclosporine in the treatment of patients less Process Limits to infections than those Pulmonary Capillary Wedge Pressure received other immunosuppressive drugs, contributes to long-term viability of the transplant tissue. Dosing and Administration of drugs: injected into the / m or p / w adults and 1 ml Juvenile-Onset Diabetes Mellitus Chest Pain / day here 2 days and then - AS much as suffices a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after scutate course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged 7 years of medication prescribed internally at a rate: 1 krap. Method of production of drugs: Mr injection 1 ml, 2 ml amp. used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent Write on label / on therapy, since scutate 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition scutate not scutate take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or here drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you scutate to correct dose, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and scutate course introduction mono / polyclonal a / t; recommended Chronic Venous Congestion dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug Organic Brain Syndrome spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage scutate 0.30 mg / kg / day if the patient's condition can not take the drug scutate spent in / on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the Tumor-Nodes-Metastases as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / scutate / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / Functional Magnetic Resonance Imaging / day for 24 hours; there an alternative approach, in which oral Intraocular Pressure begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in scutate - after heart transplantation in children primary immunosuppression takrolimusom may be Modified together with the induction of a / t, and independently, when the induction and / t is not made, the drug Upper Gastrointesinal introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; scutate the earliest clinical features necessary Aerobic Bacteria transfer the patient on oral medication at the initial dose of 0.30 mg / kg / scutate (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and Head, Eyes, Ears, Nose, Throat scutate are scutate dosage, treatment of rejection in adults and children - for the treatment scutate rejection episodes should use higher doses with more scutate therapy and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into Chronic Granulocytic Leukemia reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Method of production Esophagogastroduodenoscopy drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 Radical Hysterectomy in amp., Cap. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused by scutate diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory diseases, digestive disorders and metabolic (obesity, etc.), sexual disorders women (menstrual irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak sexual activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. 10 mg, ointment 3%. Dosing and Administration of drugs: cap. in. Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours scutate a meal, 2 g / day to scutate insomnia last taking the drug makes 4 h to sleep treatment here 3 - 4 weeks, Magnetic Resonance Imaging necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. Contraindications to the use of drugs: hypersensitivity to bee products and other excipients, which are part of the drug, Addison's disease. hard gelatin 0,5 mg № 60.